Nav: Home

Case study: Treating COVID-19 in a patient with multiple myeloma

April 03, 2020

A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms.

The patient, a 60-year-old male who had been diagnosed with multiple myeloma in 2015 and was on maintenance therapy, was hospitalized in February for chest tightness and shortness of breath. Although he did not show symptoms of cough or fever, he tested positive for COVID-19 and his illness was classified as severe.

Treatment with antiviral and corticosteroid therapies did not fully resolve his symptoms. On the second day in the hospital, a chest CT scan showed that the patient had ground glass opacities in his lungs, which are a characteristic of pneumonia. His levels of interleukin-6 (IL-6), a pro-inflammatory cytokine, were high. After one intravenous administration of tocilizumab, the patient's IL-6 levels decreased. Three days after tocilizumab treatment, his chest tightness had resolved; 10 days later, his CT scan had cleared and he was discharged from the hospital.

"Our patients with hematologic malignancies are immunosuppressed, which may put them at higher risk for novel coronavirus infection. What are the characteristics of COVID-19 in patients with blood cancers? What is the optimal treatment approach? Everything is unknown, and that was the motivation for this study," said Changcheng Zheng, MD, of the University of Science and Technology of China and the study's lead author.

Tocilizumab is commonly used to treat cytokine release syndrome, a systemic inflammatory response that occurs in response to treatment with certain types of immunotherapies. Dr. Zheng and his team suggest the agent may treat COVID-19 by addressing the acute severe inflammatory response, or "cytokine storm," that the virus triggers. However, they emphasize the need for more research into the potential mechanisms of action.

Dr. Zheng also suggests that because the patient had chest tightness and shortage of breath without other COVID-19 symptoms, specifically cough and fever, clinical symptoms of the virus may not be typical in patients who have hematologic malignancies.

The research team hopes this case study may offer insights and stimulate more research. "Tocilizumab was effective in the treatment of COVID-19 in this patient with multiple myeloma, but further prospective and randomized clinical trials are needed to verify the findings," said Dr. Zheng.

In March 2020, the FDA approved a randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the safety and efficacy of intravenous tocilizumab for the treatment of adult patients with COVID-19.
-end-
Blood Advances, is a peer-reviewed, online only, open access journal of the American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders.

Blood Advances® is a registered trademark of the American Society of Hematology.

American Society of Hematology

Related Multiple Myeloma Articles:

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.
New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.
Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.
New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.
BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.
Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.
NEJM publishes bb2121 Phase 1 data in patients with multiple myeloma
Celgene Corporation and bluebird bio announce results from ongoing multicenter Phase 1 study of bb2121 anti-BCMA CAR T cell therapy in patients with multiple myeloma published in the New England Journal of Medicine.
Multiple myeloma: DNA rearrangement may predict poor outcomes
In multiple myeloma, Ig lambda translocations may indicate poor outcomes and resistance to immunomodulatory drugs such as lenalidomide.
Computational platform optimizes multiple myeloma treatments
Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer.
Screening high-risk individuals can reduce multiple myeloma mortality
Multiple myeloma is a rare incurable disease that is diagnosed in more than 30,000 people each year in the United States.
More Multiple Myeloma News and Multiple Myeloma Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.